JRJoseph Matthew Rogers

Joseph Matthew Rogers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joseph Matthew Rogers has a total of 151 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    De novo macrocyclic peptide discovery produces potent class A GPCR ligands with diverse pharmacology

    by Fernando Salgado-Polo, Marin Matic, Philip Ben Rainsford, Felix Faas, Max Meyrath, Rajesh Regmi, Mette M Rosenkilde, Martyna Szpakowska, Andy Chevigné, Alexander S Hauser, et al.

    G protein-coupled receptors (GPCRs) represent one of the largest protein families of therapeutic importance, as over one third of all currently approved drugs target GPCRs. A growing proportion of GPCR drugs are peptides. However, class A GPCRs (over 80% of clinically studied targets) are underexploited as peptide targets, presumably since their only structured domain is the core, seven-helix, integral membrane fold presenting a limited solvent-exposed surface area. Screening libraries of de novo macrocyclic peptides have allowed for the targeting of otherwise intractable proteins, but their potential to generate selective ligands for class A GPCRs has not been demonstrated. Here, we used random nonstandard peptides integrated discovery (RaPID) to identify de novo macrocyclic peptide ligands targeting the chemokine receptor CXCR4. CXCR4 regulates cell migration, immune surveillance, and inflammation, making it an important therapeutic target for multiple diseases. We discovered novel, potent CXCR4-selective antagonists binding within the orthosteric pocket with nanomolar affinity. The most active peptides effectively inhibited receptor signaling, suppressed chemokine-driven cell migration, and blocked CXCR4-driven HIV entry. Our results show that even the structurally minimal class A GPCRs are viable targets for de novo cyclic peptide discovery, highlighting the potential for uncovering ligands towards other members of the GPCR superfamily.

  • Open Access

    Proteome-scale quantification of the interactions driving condensate formation of intrinsically disordered proteins

    by Rasmus K. Norrild, Sören von Bülow, Baptiste Zanchet, Einar Halldórsson, Kresten Lindorff-Larsen, Joseph M. Rogers, Alexander K. Buell

    Cellular organization in the form of biomolecular condensates is a fundamental regulatory mechanism across all forms of life. Formation of condensates relies on multivalent interactions that are often weak and transient, making them challenging to study experimentally. We have developed Condensate Partitioning by mRNA-Display (CPmD) to measure these interactions from the partition free energies of peptides and nucleic acids into reconstituted condensates. CPmD increases experimental throughput by several orders of magnitude, and we apply it to reveal the interactions driving condensate formation of intrinsically disordered proteins. We show that the partition free energies of about one hundred thousand peptides derived from the disordered proteome into a model condensate directly reflect their intrinsic propensity to form condensates. We reveal that amino acid content, linked to hydrophobicity, is the primary determinant of phase behavior. Additionally, CPmD uniquely resolves subtle sequence-dependent contributions that can encode specificity. CPmD thus provides a powerful tool to decipher how weak interactions between protein and RNA regulate biological function through condensate formation.


  • Open Access

    Display selection of peptide ligands for helical aromatic foldamers

    by Lingfei Wang, Joseph M. Rogers, Simon J. Dawson, Line M. Langhorn, Ryan T. Howard, Sunbum Kwon, Céline Douat, Hiroaki Suga, Ivan Huc

    Display selection allowed for the identification of peptides with a lariat structure that bind to aromatic foldamer helices both sequence-selectively and diastereoselectively.


  • Open Access

    Proteome-scale quantification of the interactions driving condensate formation of intrinsically disordered proteins

    by Rasmus K. Norrild, Soeren von Buelow, Einar Halldórsson, Kresten Lindorff-Larsen, Joseph M. Rogers, Alexander K. Buell

    Intrinsically disordered protein regions facilitate cellular organization through phase separation into biomolecular condensates. However, the molecular interactions driving this process remain poorly understood because of experimental limitations. Here, we advance experimental throughput by several orders of magnitude by developing Condensate Partitioning by mRNA-Display (CPmD). The method allows analysis of partitioning of hundred thousand peptides derived from the disordered proteome into reconstituted condensates. Our results demonstrate that the amino acid content, rather than specific sequence, primarily determines partitioning behavior. Importantly, quantification of the partitioning energies of peptides allows us to decipher the ‘molecular grammar’ of the relevant interactions, allowing accurate prediction of the formation of condensates of diverse full-length disordered protein regions. The results reveal how physicochemical properties of disordered regions encode biological functions through formation of biomolecular condensates.


  • Special Issue on RNA‐Based Catalysts that Revolutionized the Discovery of Bioactive Peptides

    by Seino A. K. Jongkees, Joseph M. Rogers, Louise J. Walport

  • Mixed Stereochemistry Macrocycle Acts as a Helix-Stabilizing Peptide N-Cap

    by Fabian Hink, Julen Aduriz-Arrizabalaga, Xabier Lopez, Hiroaki Suga, David De Sancho, Joseph M. Rogers

    Interactions between proteins and α-helical peptides have been the focus of drug discovery campaigns. However, the large interfaces formed between multiple turns of an α-helix and a binding protein represent a significant challenge to inhibitor discovery. Modified peptides featuring helix-stabilizing macrocycles have shown promise as inhibitors of these interactions. Here, we tested the ability of N-terminal to side-chain thioether-cyclized peptides to inhibit the α-helix binding protein Mcl-1, by screening a trillion-scale library. The enriched peptides were lariats featuring a small, four-amino-acid N-terminal macrocycle followed by a short linear sequence that resembled the natural α-helical Mcl-1 ligands. These "Heliats" (helical lariats) bound Mcl-1 with tens of nM affinity, and inhibited the interaction between Mcl-1 and a natural peptide ligand. Macrocyclization was found to stabilize α-helical structures and significantly contribute to affinity and potency. Yet, the 2nd and 3rd positions within the macrocycle were permissible to sequence variation, so that a minimal macrocyclic motif, of an N-acetylated d-phenylalanine at the 1st position thioether connected to a cysteine at the 4th, could be grafted into a range of peptides and stabilize helical conformations. We found that d-stereochemistry is more helix-stabilizing than l- at the 1st position in the motif, as the d-amino acid can utilize polyproline II torsional angles that allow for more optimal intrachain hydrogen bonding. This mixed stereochemistry macrocyclic N-cap is synthetically accessible, requiring only minor modifications to standard solid-phase peptide synthesis, and its compatibility with peptide screening can provide ready access to helix-focused peptide libraries for de novo inhibitor discovery.


  • Open Access

    Mixed stereochemistry macrocycle acts as a helix-stabilizing peptide N-cap

    by Fabian Hink, Julen Aduriz-Arrizabalaga, Xabier Lopez, Hiroaki Suga, David De Sancho, Joseph Matthew Rogers

    Interactions between proteins and α-helical peptides are abundant in the human cell. Many of these interactions are linked to disease and have been the focus of drug discovery campaigns. However, the large interfaces formed between multiple turns of α-helix and a binding protein represent a significant challenge to inhibitor discovery. Modified peptides featuring helix-stabilizing macrocycles have shown promise as inhibitors of these interactions. Here, we tested the ability of N-terminal to side-chain thioether-cyclized peptides to inhibit the α-helix binding protein Mcl-1, by screening a trillion-scale peptide library using RaPID technology. The top enriched peptides were lariats, featuring a small, four amino acid N-terminal macrocycle followed by a short linear sequence that resembled the natural α-helical Mcl-1 ligands. These ‘Heliats’ (Helical lariats) bound Mcl-1 with mid-nM affinity, and inhibited the interaction between Mcl-1 and a natural peptide ligand. Macrocyclization was found to stabilize α-helical structures, and significantly contribute to affinity and potency. Yet, the 2nd and 3rd positions within the macrocycle were permissible to sequence variation, so that a minimal macrocyclic motif, of an N-acetylated D-phenylalanine at the 1st position thioether connected a cysteine at the 4th, could be grafted into a natural peptide and stabilize helical conformations. We found that D-stereochemistry is more helix-stabilizing than L- at the 1st position in the motif, as the D-amino acid can utilize polyproline II torsional angles that allow for more optimal intrachain hydrogen bonding. This mixed stereochemistry macrocyclic N-cap is synthetically accessible, requiring only minor modifications to standard solid-phase peptide synthesis, and its compatibility with RaPID peptide screening can provide ready access to helix-focused peptide libraries for de novo inhibitor discovery.

  • Top Cited Papers
    Open Access

    De novo design of high-affinity binders of bioactive helical peptides

    by Susana Vázquez Torres, Philip J. Y. Leung, Preetham Venkatesh, Isaac D. Lutz, Fabian Hink, Huu-Hien Huynh, Jessica Becker, Andy Hsien-Wei Yeh, David Juergens, Nathaniel R. Bennett, et al.

    Many peptide hormones form an α-helix on binding their receptors1–4, and sensitive methods for their detection could contribute to better clinical management of disease5. De novo protein design can now generate binders with high affinity and specificity to structured proteins6,7. However, the design of interactions between proteins and short peptides with helical propensity is an unmet challenge. Here we describe parametric generation and deep learning-based methods for designing proteins to address this challenge. We show that by extending RFdiffusion8 to enable binder design to flexible targets, and to refining input structure models by successive noising and denoising (partial diffusion), picomolar-affinity binders can be generated to helical peptide targets by either refining designs generated with other methods, or completely de novo starting from random noise distributions without any subsequent experimental optimization. The RFdiffusion designs enable the enrichment and subsequent detection of parathyroid hormone and glucagon by mass spectrometry, and the construction of bioluminescence-based protein biosensors. The ability to design binders to conformationally variable targets, and to optimize by partial diffusion both natural and designed proteins, should be broadly useful.


  • Open Access

    Substrates and Cyclic Peptide Inhibitors of the Oligonucleotide‐Activated Sirtuin 7**

    by Julie E. Bolding, Alexander L. Nielsen, Iben Jensen, Tobias N. Hansen, Line A. Ryberg, Samuel T. Jameson, Pernille Harris, Günther H. J. Peters, John M. Denu, Joseph M. Rogers, et al.

    The sirtuins are NAD+‐dependent lysine deacylases, comprising seven isoforms (SIRT1–7) in humans, which are involved in the regulation of a plethora of biological processes, including gene expression and metabolism. The sirtuins share a common hydrolytic mechanism but display preferences for different ϵ‐N‐acyllysine substrates. SIRT7 deacetylates targets in nuclei and nucleoli but remains one of the lesser studied of the seven isoforms, in part due to a lack of chemical tools to specifically probe SIRT7 activity. Here we expressed SIRT7 and, using small‐angle X‐ray scattering, reveal SIRT7 to be a monomeric enzyme with a low degree of globular flexibility in solution. We developed a fluorogenic assay for investigation of the substrate preferences of SIRT7 and to evaluate compounds that modulate its activity. We report several mechanism‐based SIRT7 inhibitors as well as de novo cyclic peptide inhibitors selected from mRNA‐display library screening that exhibit selectivity for SIRT7 over other sirtuin isoforms, stabilize SIRT7 in cells, and cause an increase in the acetylation of H3 K18.